Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Esperion Theraptc
(NQ:
ESPR
)
25.55
USD
-1.20 (-4.49%)
Official Closing Price
Updated: 7:58 PM EST, Jan 15, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Esperion Theraptc
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Kaskela Law LLC: Shareholder Class Action Filed Against Esperion Therapeutics, Inc. - ESPR
May 07, 2018
Kaskela Law LLC announces that a shareholder class action lawsuit has been filed against Esperion Therapeutics, Inc. (NASDAQ:ESPR) (“Esperion” or the “Company”) on behalf of purchasers of the Company’s...
From
GlobeNewswire News Releases
Pomerantz Law Firm Announces the Filing of a Class Action against Esperion Therapeutics, Inc. and Certain Officers – ESPR
May 07, 2018
Pomerantz LLP announces that a class action lawsuit has been filed against Esperion Therapeutics, Inc. (“Esperion” or the “Company”) (NASDAQ:ESPR) and certain of its officers. The class action, filed...
From
GlobeNewswire News Releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Esperion Therapeutics, Inc. - ESPR
May 07, 2018
From
ACCESSWIRE
Esperion to Participate in Fireside Chat at the Deutsche Bank 43rd Annual Health Care Conference
May 04, 2018
Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with...
From
GlobeNewswire News Releases
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Esperion Therapeutics, Inc. (ESPR)
May 03, 2018
From
ACCESSWIRE
Important Stock Score Report Updates for Esperion Therapeutics, Integrated Media Technology, Mastercard, Molson Coors, and Wayfair
May 03, 2018
InvestorsObserver issues critical PriceWatch Alerts for ESPR, IMTE, MA, TAP, and W.
From
PR Newswire
Stock Review for Biotech's Investors -- BioTime, Eleven Biotherapeutics, Endocyte, and Esperion Therapeutics
May 02, 2018
From
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Esperion Therapeutics, Inc. - ESPR
May 02, 2018
Pomerantz LLP is investigating claims on behalf of investors of Esperion Therapeutics, Inc. ("Esperion" or the "Company") (NASDAQ: ESPR). Such investors are advised to contact Robert S. Willoughby at...
From
PR Newswire
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Esperion Therapeutics, Inc. (ESPR)
May 02, 2018
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Esperion Therapeutics, Inc. ("Esperion" or the "Company") (NASDAQ: ESPR). Such...
From
PR Newswire
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter 2018 Financial Results
May 02, 2018
Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with...
From
GlobeNewswire News Releases
Esperion Announces Positive Top-Line Results from Pivotal Phase 3 Long-Term Safety Study of Bempedoic Acid
May 02, 2018
Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with...
From
GlobeNewswire News Releases
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 13, 2018
Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with...
From
GlobeNewswire News Releases
Investor Expectations to Drive Momentum within Esperion Therapeutics, Celestica, Sapiens International Corporation N.V, Royal Bank Of Canada, CSS Industries, and SSR Mining — Discovering Underlying Fa
April 09, 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Esperion Therapeutics, Inc....
From
GlobeNewswire News Releases
Pre-Market Technical Scan on Biotech Equities -- Eleven Biotherapeutics, Endocyte, Esperion Therapeutics, and Exelixis
March 28, 2018
WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on EBIO, ECYT, ESPR, and EXEL which can be accessed for free by signing up to...
From
PR Newswire
Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor in Patients with Hypercholesterolemia
March 27, 2018
Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with...
From
GlobeNewswire News Releases
New Research Coverage Highlights Star Bulk Carriers, IPG Photonics, Mellanox Technologies, Hollysys Automation Technologies, Esperion Therapeutics, and Yirendai — Consolidated Revenues, Company Growth
March 13, 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Star Bulk Carriers Corp....
From
GlobeNewswire News Releases
Esperion to Participate in Fireside Chat at March 2018 Investor Conferences
March 07, 2018
Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with...
From
GlobeNewswire News Releases
Esperion Announces Positive Top-Line Results from First Pivotal Phase 3 Study of Bempedoic Acid
March 06, 2018
Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with...
From
GlobeNewswire News Releases
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 23, 2018
Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with...
From
GlobeNewswire News Releases
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Fourth Quarter and Full Year 2017 Financial Results
February 19, 2018
Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with...
From
GlobeNewswire News Releases
How CEO's of Biotech are Incentivized and What This Means for Investors
February 13, 2018
From
PR Newswire
Esperion to Participate in Fireside Chat at the 36th Annual J.P. Morgan Healthcare Conference
January 03, 2018
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment...
From
GlobeNewswire News Releases
Esperion Announces the Appointment of Jeffrey Berkowitz to Board of Directors
December 14, 2017
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment...
From
GlobeNewswire News Releases
Biotech's Flying Under The Radar
December 06, 2017
MicroCapSpeculators.com News Commentary
From
PR Newswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
December 01, 2017
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment...
From
GlobeNewswire News Releases
Esperion to Participate in Fireside Chat at the Jefferies 2017 London Healthcare Conference
November 13, 2017
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment...
From
GlobeNewswire News Releases
Esperion to Participate in Fireside Chat at the Stifel 2017 Healthcare Conference
November 09, 2017
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment...
From
GlobeNewswire News Releases
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2017 Financial Results
November 07, 2017
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment...
From
GlobeNewswire News Releases
Esperion Announces Initiation of Pivotal Phase 3 Study for the Bempedoic Acid / Ezetimibe Combination Pill
November 06, 2017
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment...
From
GlobeNewswire News Releases
Biotech Stocks on Investors' Radar -- Curis, Egalet, Esperion Therapeutics, and GlycoMimetics
November 02, 2017
From
PR Newswire
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.